NDAINTRAVENOUSSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE (norepinephrine bitartrate) by Baxter International is (alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action). First approved in 2022.
Drug data last refreshed 11h ago · AI intelligence enriched 14h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Norepinephrine bitartrate in 0.9% sodium chloride is an intravenous catecholamine solution approved by the FDA in September 2022. It works through dual alpha-adrenergic and beta-adrenergic mechanisms to increase blood pressure and cardiac output. This drug is indicated for acute hypotensive states requiring rapid hemodynamic support in critical care settings.
Peak12.6 years to LOE
Product is in peak commercial phase with established market presence; commercial teams are likely focused on maintaining market share and expanding adoption in hospital systems.
Mechanism of Action
(alpha-adrenergic action) and an inotropic stimulator of the heart and dilator of coronary arteries (beta-adrenergic action).
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on norepinephrine bitartrate positions you in the high-stakes critical care market where clinical impact is immediate and tangible. Roles typically involve direct engagement with ICU physicians, hospital procurement teams, and anesthesiologists—offering strong clinical credibility and specialized expertise in hemodynamic management.
Hospital Account ManagerCritical Care Specialist
Worked on NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE at Baxter International? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.